DDrare: Database of Drug Development for Rare Diseases

ID	Disease name (Link within this page)	Number of trials
96	Crohn disease	2

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	EUCTR2006-002027-16-GR (EUCTR)	12/12/2006	05/09/2006	Certolizumab pegol 400 mg monthly in the treatment of adult Greek patients with moderate to severe Crohn’s Disease, who have been previously treated successfully with infliximab but who have subsequently lost the response or have developed intolerance to infliximab: an open-label, multi-center, single-cohort study to evaluate efficacy, safety and onset of action.	Certolizumab pegol 400 mg monthly in the treatment of adult Greek patients with moderate to severe Crohn’s Disease, who have been previously treated successfully with infliximab but who have subsequently lost the response or have developed intolerance to infliximab: an open-label, multi-center, single-cohort study to evaluate efficacy, safety and onset of action.	Certolizumab pegol in the treatment of adult Greek patients with moderate to severe Crohn’s Disease, who have been previously treated successfully with infliximab but who have subsequently lost the response or have developed intolerance to infliximab	Product Name: certolizumab pegol Product Code: CDP870	UCB AE	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes			Greece
2	NCT00349752 (ClinicalTrials.gov)	November 2006	30/6/2006	Corticosteroid Sparing Effect of Certolizumab in Crohn's Disease	A Phase IIIb Multicenter, Double-blind, Placebo-controlled,Randomized Trial to Examine the Corticosteroid-sparing Effect of Certolizumab Pegol in Patients With Moderate to Severe Crohn's Disease.	Crohn's Disease	Biological: certolizumab pegol 400 mg;Other: Placebo	UCB Pharma	NULL	Terminated	18 Years	N/A	All	174	Phase 3	United States;Canada;Germany;Belgium

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

EUCTR2006-002027-16-GR
(EUCTR)

12/12/2006

05/09/2006

Certolizumab pegol 400 mg monthly in the treatment of adult Greek patients with moderate to severe Crohn’s Disease, who have been previously treated successfully with infliximab but who have subsequently lost the response or have developed intolerance to infliximab: an open-label, multi-center, single-cohort study to evaluate efficacy, safety and onset of action.

Certolizumab pegol in the treatment of adult Greek patients with moderate to severe Crohn’s Disease, who have been previously treated successfully with infliximab but who have subsequently lost the response or have developed intolerance to infliximab

Product Name: certolizumab pegol
Product Code: CDP870

UCB AE

NULL

Authorised-recruitment may be ongoing or finished

Female: yes
Male: yes

Greece

NCT00349752
(ClinicalTrials.gov)

November 2006

30/6/2006

Corticosteroid Sparing Effect of Certolizumab in Crohn's Disease

A Phase IIIb Multicenter, Double-blind, Placebo-controlled,Randomized Trial to Examine the Corticosteroid-sparing Effect of Certolizumab Pegol in Patients With Moderate to Severe Crohn's Disease.

Crohn's Disease

Biological: certolizumab pegol 400 mg;Other: Placebo

UCB Pharma

NULL

Terminated

18 Years

N/A

All

174

Phase 3

United States;Canada;Germany;Belgium